Japanese pharma company wins arbitration over cancer drug
16-08-2022
Texas jury says 3Shape must pay $12m over dental scanner
12-04-2022
Texas uni wants Supreme Court to settle state sovereignty rules
12-03-2020
CrackerClips Stock Media / Shutterstock.com
Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Daiichi Sankyo, Seagen, cancer, oncology, patent infringement, Rodney Gilstrap, biotech, AstraZeneca
